
Sign up to save your podcasts
Or


On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Tim Opler, Eric Schmidt and Sam Fazeli are joined by special guests Jacob Plieth and Madeleine Armstrong for a deep dive into ASCO 2024, including the highs and lows on the data front. The hosts also discuss the shifting interests from pharma companies as some suggest T-cell engagers may have overtaken ADCs and radios in the oncology space. In non-ASCO news, the group covers NASH data from Lilly and Viking and Structure’s data in obesity. The hosts also discuss the latest on BioSecure Act, improving inflation numbers and pickup in the XBI, Moderna’s first vaccine approval outside of COVID, and more. This episode aired on June 7, 2024.
By Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more4.4
1818 ratings
On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Tim Opler, Eric Schmidt and Sam Fazeli are joined by special guests Jacob Plieth and Madeleine Armstrong for a deep dive into ASCO 2024, including the highs and lows on the data front. The hosts also discuss the shifting interests from pharma companies as some suggest T-cell engagers may have overtaken ADCs and radios in the oncology space. In non-ASCO news, the group covers NASH data from Lilly and Viking and Structure’s data in obesity. The hosts also discuss the latest on BioSecure Act, improving inflation numbers and pickup in the XBI, Moderna’s first vaccine approval outside of COVID, and more. This episode aired on June 7, 2024.

32,100 Listeners

537 Listeners

766 Listeners

124 Listeners

337 Listeners

60 Listeners

85 Listeners

34 Listeners

149 Listeners

63 Listeners

15 Listeners

13 Listeners

15 Listeners

8 Listeners

50 Listeners